Went public 8/8/2000 at $16 per share
Filing Range: 6 mil. shares @ $14 to $16
Shares Outstanding: 28.3 mil. shares
Underwriters: J.P. Morgan & Co. Inc./Robertson Stephens & Co./CIBC
Company Counsel: Hale & Dorr LLP
Manager Counsel: Cahill Gordon & Reindel
Auditor: Ernst & Young LLP
Develops and acquires rights to pharmaceutical compounds. The company buys the rights to drugs in their later stages of development and leads them through clinical trials, regulatory procedures and market launch. For the company, drug development begins with an analysis and definition of the prospective medical value of a product to customers. The company’s goal is to move useful products to market faster, cheaper, and with higher quality than competitors.
E.M. Warburg, Pincus & Co. LLC
Morgan Stanley Venture Partners
Biotech Capital Corp.
Robertson Stephens & Co.
Morgan Stanley Dean Witter Capital Partners LLC
Burr, Egan, Deleage & Co.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 09/01/1996 2 Early Stage 4500.0
2 06/01/1997 2 Expansion 24600.0
3 12/01/1997 2 Expansion 10000.0
4 08/14/1998 13 Buyout/Acquisition 36153.9
5 10/19/1999 8 Later Stage 6000.0
6 03/02/2000 6 Later Stage 13343.2
7 05/17/2000 3 Later Stage 6100.0
(Data in $ millions)
Total Revenues: $0.0
Net Income: -34.7